Cell Reports MedicinePub Date : 2025-03-18Epub Date: 2025-02-22DOI: 10.1016/j.xcrm.2025.102026
Mercedes Guerrero-Murillo, Aina Rill-Hinarejos, Juan L Trincado, Alex Bataller, Valentín Ortiz-Maldonado, Daniel Benítez-Ribas, Marta Español-Rego, E Azucena González-Navarro, Nuria Martínez-Cibrián, Doménica Marchese, Lourdes Martín-Martín, Alejandro Martín García-Sancho, Susana Rives, Holger Heyn, Manel Juan, Álvaro Urbano-Ispizúa, Julio Delgado, Alberto Orfao, Elisabetta Mereu, Clara Bueno, Pablo Menendez
{"title":"Integrative single-cell multi-omics of CD19-CAR<sup>pos</sup> and CAR<sup>neg</sup> T cells suggest drivers of immunotherapy response in B cell neoplasias.","authors":"Mercedes Guerrero-Murillo, Aina Rill-Hinarejos, Juan L Trincado, Alex Bataller, Valentín Ortiz-Maldonado, Daniel Benítez-Ribas, Marta Español-Rego, E Azucena González-Navarro, Nuria Martínez-Cibrián, Doménica Marchese, Lourdes Martín-Martín, Alejandro Martín García-Sancho, Susana Rives, Holger Heyn, Manel Juan, Álvaro Urbano-Ispizúa, Julio Delgado, Alberto Orfao, Elisabetta Mereu, Clara Bueno, Pablo Menendez","doi":"10.1016/j.xcrm.2025.102026","DOIUrl":"10.1016/j.xcrm.2025.102026","url":null,"abstract":"","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102026"},"PeriodicalIF":11.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cell Reports MedicinePub Date : 2025-03-18Epub Date: 2025-03-03DOI: 10.1016/j.xcrm.2025.101989
Marco M Buttigieg, Caitlyn Vlasschaert, Alexander G Bick, Robert J Vanner, Michael J Rauh
{"title":"Inflammatory reprogramming of the solid tumor microenvironment by infiltrating clonal hematopoiesis is associated with adverse outcomes.","authors":"Marco M Buttigieg, Caitlyn Vlasschaert, Alexander G Bick, Robert J Vanner, Michael J Rauh","doi":"10.1016/j.xcrm.2025.101989","DOIUrl":"10.1016/j.xcrm.2025.101989","url":null,"abstract":"<p><p>Clonal hematopoiesis (CH)-the expansion of somatically mutated hematopoietic cells-is common in solid cancers. CH is associated with systemic inflammation, but its impact on tumor biology is underexplored. Here, we report the effects of CH on the tumor microenvironment (TME) using 1,550 treatment-naive patient samples from the Clinical Proteomics Tumor Analysis Consortium (CPTAC) cohort. CH is present in 18.3% of patients, with one-third of CH mutations also detectable in tumor-derived DNA from the same individual (CH-Tum), reflecting CH-mutant leukocyte infiltration. Across cancers, the presence of CH-Tum is associated with worse survival outcomes. Molecular analyses reveal an association between CH-Tum and an immune-rich, inflammatory TME that is notably distinct from age-related gene expression changes. These effects are most prominent in glioblastoma, where CH correlates with pronounced macrophage infiltration, inflammation, and an aggressive, mesenchymal phenotype. Our findings demonstrate that CH shapes the TME, with potential applications as a biomarker in precision oncology.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"101989"},"PeriodicalIF":11.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cell Reports MedicinePub Date : 2025-03-18Epub Date: 2025-03-10DOI: 10.1016/j.xcrm.2025.102002
Jue Zhang, Diana Marcela Tabima, David Vereide, Weifeng Zeng, Nicholas J Albano, Sarah Lyon, Peter J Nicksic, Ellen C Shaffrey, Robert E George, Mitchell D Probasco, Elizabeth S Perrin, Yiyang Xu, Matthew E Brown, Ron Stewart, Naomi C Chesler, Lih-Sheng Turng, Samuel O Poore, Igor I Slukvin, James A Thomson, John P Maufort
{"title":"Small-diameter artery grafts engineered from pluripotent stem cells maintain 100% patency in an allogeneic rhesus macaque model.","authors":"Jue Zhang, Diana Marcela Tabima, David Vereide, Weifeng Zeng, Nicholas J Albano, Sarah Lyon, Peter J Nicksic, Ellen C Shaffrey, Robert E George, Mitchell D Probasco, Elizabeth S Perrin, Yiyang Xu, Matthew E Brown, Ron Stewart, Naomi C Chesler, Lih-Sheng Turng, Samuel O Poore, Igor I Slukvin, James A Thomson, John P Maufort","doi":"10.1016/j.xcrm.2025.102002","DOIUrl":"10.1016/j.xcrm.2025.102002","url":null,"abstract":"<p><p>Autologous vascular grafts, the only clinically approved option for small-diameter (<6 mm) revascularizations, require invasive harvesting and have limited availability and variable quality. To address these challenges, we develop a 3-mm-diameter artery graft by using arterial endothelial cells (AECs) derived from pluripotent stem cells (PSCs). After establishing technologies for pure AEC generation and expanded polytetrafluoroethylene (ePTFE) graft coating, we engineer artery grafts by seeding the inner lumen of ePTFE vascular grafts with either major histocompatibility complex (MHC) mismatched unmodified-wild-type (MHC-WT) AECs or MHC class I/II double knockout (MHC-DKO) AECs. Their function is evaluated in a rhesus arterial interposition grafting model. MHC-WT grafts maintained 100% patency for 6 months, significantly better than naked and MHC-DKO grafts. Additionally, the endothelium of MHC-WT grafts is repopulated with host cells, supporting long-term patency. Collectively, our study demonstrates that PSC-derived MHC-WT artery grafts provide an unlimited homogenous resource for allogeneic arterial revascularization.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102002"},"PeriodicalIF":11.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"BET inhibitor in combination with BCG vaccine enhances antitumor efficacy and orchestrates T cell reprogramming for melanoma.","authors":"Wenhua Wang, Xin Li, Rui Hu, Liang Dong, Shiyao Pei, Liping Jin, Qian Gao, Xiang Chen, Mingzhu Yin","doi":"10.1016/j.xcrm.2025.101995","DOIUrl":"10.1016/j.xcrm.2025.101995","url":null,"abstract":"<p><p>Immunotherapy shows remarkable benefits in treating melanoma, yet existing approaches achieve limited overall responses. Here, we show that a combination of bromodomain and extra-terminal protein family inhibitor, NHWD-870, and Bacillus Calmette-Guérin vaccine is a promising therapeutic strategy for melanomas. Single-cell transcriptome analyses and functional experiments show that the combination therapy significantly inhibited tumor growth by reprogramming T cells toward an immune-activated state, enhancing their cytotoxicity, preventing their exhaustion, and increasing the recruitment of them into the tumor microenvironment. We identify the molecule, MT1, as a direct downstream target of BRD4, which is effectively suppressed by NHWD-870. Furthermore, our findings are reinforced by a humanized patient-derived xenograft (PDX) model, which exhibits notable antitumor effects in humanized tumor-bearing mice treated with the combination therapy. Our study underscores the immense potential of this therapeutic approach for clinical practice, offering promising prospects in overcoming the limitations of current treatments.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":"6 3","pages":"101995"},"PeriodicalIF":11.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cell Reports MedicinePub Date : 2025-03-18Epub Date: 2025-02-24DOI: 10.1016/j.xcrm.2025.101978
Jingbo Wang, Xuemin Shen, Qifan Ma, Lin Yang, Xiaoyu Zhou, Luting Wang, Junqi Cui, Chunye Zhang, Guojun Li, Neil Gross, Siyi Li, Ruimin Huang, Changyou Zhan, Zhen Cheng, Kun Wang, Jie Tian, Ying Yuan, Xiaofeng Tao
{"title":"Near-infrared fluorescence imaging with an MET-targeting probe for biopsy site selection in patients with oral potentially malignant disorders.","authors":"Jingbo Wang, Xuemin Shen, Qifan Ma, Lin Yang, Xiaoyu Zhou, Luting Wang, Junqi Cui, Chunye Zhang, Guojun Li, Neil Gross, Siyi Li, Ruimin Huang, Changyou Zhan, Zhen Cheng, Kun Wang, Jie Tian, Ying Yuan, Xiaofeng Tao","doi":"10.1016/j.xcrm.2025.101978","DOIUrl":"10.1016/j.xcrm.2025.101978","url":null,"abstract":"<p><p>Accurate detection of malignant transformation in oral potentially malignant disorders (OPMDs) is crucial for guiding effective treatment and improving patient management. This study evaluates the potential of MET-binding peptide-indocyanine green (cMBP-ICG), a mesenchymal-epithelial transition factor (MET)-targeted near-infrared fluorescence imaging (NIRFI) probe, for biopsy site selection in OPMDs. Preclinical results demonstrate the superior accuracy of NIRFI-assisted biopsy over conventional oral examination (COE)-based biopsy in detecting high-grade dysplasia (HGD) or squamous cell carcinoma (SCC) and reducing missed detection rates. In a clinical trial with 50 patients, NIRFI-assisted biopsy achieves significantly higher diagnostic accuracy compared to COE-based biopsy (91% vs. 72%, p = 0.0005). These findings underscore the importance of NIRFI in enhancing diagnostic precision, supporting early detection and enabling timely and accurate treatment interventions for patients with OPMDs. The clinical trial is registered under the registration number ChiCTR2300074454.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"101978"},"PeriodicalIF":11.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143499512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B α1/2 shedding.","authors":"Rui Wang, Jingni Wu, Yifeng Lin, Yufei Xiao, Bin Yang, Sheng Yao, Tianhui Pan, Zhixuan Fu, Shuyu Li, Caihua Wang, Yongliang Zhu","doi":"10.1016/j.xcrm.2025.101981","DOIUrl":"10.1016/j.xcrm.2025.101981","url":null,"abstract":"<p><p>Antigenic peptide-based mRNA vaccines have been explored for immunotherapeutic use in various types of cancer because of their advantages in activating durable and specific immune responses. However, their role in modulating tumor metastasis is still unclear. Here, we identify a conserved linear epitope-based peptide, Ma3P, located in the proteolytic region of major histocompatibility complex (MHC) class I-related chain A (MICA) α3 and further design mCM10-L, an mRNA vaccine that encodes the carrier protein CRM197 and 10 tandem repeats of Ma3P. We demonstrate that vaccination with mCM10-L induces the production of specific antibodies that block MICA/B α1/2 shedding, activate CD8<sup>+</sup> T cells and natural killer (NK) cells, and significantly inhibit MICA/B<sup>+</sup> tumor metastasis in mice. Furthermore, mCM10-L stimulation triggers the production of specific antibodies to promote MICA/B-mediated immune killing in an in-vitro-interacting human organoid model and humanized mice. Our results indicate the potential clinical application prospects of the mCM10-L vaccine.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"101981"},"PeriodicalIF":11.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143499449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cell Reports MedicinePub Date : 2025-03-18Epub Date: 2025-03-06DOI: 10.1016/j.xcrm.2025.101990
Tian Gao, Xinyu He, Junyi Wang, Jiayong Liu, Xiongbing Hu, Chujie Bai, Shenyi Yin, Yunfei Shi, Yanmin Wang, Zhichao Tan, Fang Cao, Shu Li, Yan-Jie Shi, Ruifeng Xue, Juan Li, Yang He, Jiaxin Li, Huinan Lu, Hanshuo Zhang, Lu Zhang, Zhiwei Fang, Xinyu Wang, Mengmeng Liu, Wenjun Fu, Lei Tang, Buqing Ye, Zhengfu Fan, Jianzhong Jeff Xi
{"title":"Self-assembled patient-derived tumor-like cell clusters for personalized drug testing in diverse sarcomas.","authors":"Tian Gao, Xinyu He, Junyi Wang, Jiayong Liu, Xiongbing Hu, Chujie Bai, Shenyi Yin, Yunfei Shi, Yanmin Wang, Zhichao Tan, Fang Cao, Shu Li, Yan-Jie Shi, Ruifeng Xue, Juan Li, Yang He, Jiaxin Li, Huinan Lu, Hanshuo Zhang, Lu Zhang, Zhiwei Fang, Xinyu Wang, Mengmeng Liu, Wenjun Fu, Lei Tang, Buqing Ye, Zhengfu Fan, Jianzhong Jeff Xi","doi":"10.1016/j.xcrm.2025.101990","DOIUrl":"10.1016/j.xcrm.2025.101990","url":null,"abstract":"<p><p>Several patient-derived tumor models have emerged recently. However, soft tissue sarcomas (STSs) present a challenge in developing preclinical drug-testing models due to their non-epithelial and complex nature. Here, we report a model termed patient-derived tumor-like cell clusters (PTCs) derived from STS patients. PTCs result from the self-assembly and proliferation of mesenchymal stem cells (MSCs), epithelial cells, and immune cells, faithfully recapitulating the morphology and function of the original tumors. Through standardized culture and drug-response assessment protocols, PTCs facilitate personalized drug testing, evaluating hundreds of therapies within two weeks. Notably, PTCs exhibit 100% accuracy in distinguishing between complete or partial response and disease progression. We demonstrate the utility of PTCs in guiding chemotherapy selection for a patient with relapse and metastases following conventional therapy, who exhibited a positive response after non-conventional therapy identified through PTC. These findings underscore the potential of PTCs for prospective use in clinical decision-making regarding therapy selection.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"101990"},"PeriodicalIF":11.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pharmacological rescue of mutant p53 triggers spontaneous tumor regression via immune responses.","authors":"Jiabing Li, Shuang Zhang, Baohui Wang, Yuting Dai, Jiale Wu, Dianjia Liu, Ying Liang, Shujun Xiao, Zhengyuan Wang, Jiaqi Wu, Derun Zheng, Xueqin Chen, Fangfang Shi, Kai Tan, Xianting Ding, Huaxin Song, Sujiang Zhang, Min Lu","doi":"10.1016/j.xcrm.2025.101976","DOIUrl":"10.1016/j.xcrm.2025.101976","url":null,"abstract":"<p><p>Tumor suppressor p53 is the most frequently mutated protein in cancer, possessing untapped immune-modulating capabilities in anticancer treatment. Here, we investigate the efficacy and underlying mechanisms of pharmacological reactivation of mutant p53 in treating spontaneous tumors in mice. In the p53 R279W (equivalent to the human hotspot R282W) mouse model developing spontaneous tumors, arsenic trioxide (ATO) treatment through drinking water significantly prolongs the survival of mice, dependent on p53-R279W reactivation. Transient regressions of spontaneous T-lymphomas are observed in 70% of the ATO-treated mice, accompanied by interferon (IFN) response. In allograft models, the tumor-suppressive effect of reactivated p53-R279W is detectably reduced in both immunodeficient Rag1<sup>-/-</sup> and CD8<sup>+</sup> T cell-depleted mice. ATO also activates the IFN pathway in human cancer cells harboring various p53 mutations, as well as in primary samples derived from the p53-mutant patient treated with ATO. Together, p53 could serve as an alternative therapeutic target for the development of immunotherapies.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"101976"},"PeriodicalIF":11.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cell Reports MedicinePub Date : 2025-03-18Epub Date: 2025-03-07DOI: 10.1016/j.xcrm.2025.101998
Pengyu Zong, Cindy Li, Jianlin Feng, Zhichao Yue, Nicholas Legere, Albert S Yu, Fahad Shah, Adrianna Perez, Zhu Li, Evan Jellison, Yasuo Mori, Barbara Miller, Rajkumar Verma, Bruce Liang, Lixia Yue
{"title":"TRPM2 overactivation drives hyperlipidemia-induced dysfunction of myeloid cells and neurovascular units.","authors":"Pengyu Zong, Cindy Li, Jianlin Feng, Zhichao Yue, Nicholas Legere, Albert S Yu, Fahad Shah, Adrianna Perez, Zhu Li, Evan Jellison, Yasuo Mori, Barbara Miller, Rajkumar Verma, Bruce Liang, Lixia Yue","doi":"10.1016/j.xcrm.2025.101998","DOIUrl":"10.1016/j.xcrm.2025.101998","url":null,"abstract":"<p><p>Hyperlipidemia induces cellular dysfunction and is strongly linked to various diseases. The transient receptor potential channel melastatin 2 (TRPM2) plays a critical role in endothelial injury, immune cell activation, and neuronal death. We reveal that TRPM2 expression in human peripheral leukocytes strongly correlates with plasma lipid levels. In middle-aged Apoe<sup>-/-</sup> mice, global, myeloid, and endothelial TRPM2 knockout or TRPM2 inhibition abolishes the hyperlipidemia-induced exacerbation of ischemic brain injury suggesting that TRPM2 overactivity caused by hyperlipidemia predisposes these cells to dysfunction during ischemia. Using a clinically relevant ischemic brain injury mouse model, we demonstrate TRPM2's pivotal role in mediating hyperlipidemia's detrimental effects on myeloid cells and neurovascular units. Our findings suggest that TRPM2 is a promising therapeutic target for alleviating neurodegenerative diseases exacerbated by hyperlipidemia, such as ischemic stroke. These results also highlight TRPM2 expression in peripheral blood as a potential biomarker for predicting stroke outcomes in hyperlipidemic patients.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"101998"},"PeriodicalIF":11.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cell Reports MedicinePub Date : 2025-03-18Epub Date: 2025-03-07DOI: 10.1016/j.xcrm.2025.102001
Caleb Mayer, Olivia Walch, Walter Dempsey, Kevin Hannay, Caroline Clingan, Zoe Bowen, Michelle Rozwadowski, Zachery R Reichert, N Lynn Henry, Joshi J Alumkal, Muneesh Tewari, Daniel B Forger, Sung Won Choi
{"title":"A circadian and app-based personalized lighting intervention for the reduction of cancer-related fatigue.","authors":"Caleb Mayer, Olivia Walch, Walter Dempsey, Kevin Hannay, Caroline Clingan, Zoe Bowen, Michelle Rozwadowski, Zachery R Reichert, N Lynn Henry, Joshi J Alumkal, Muneesh Tewari, Daniel B Forger, Sung Won Choi","doi":"10.1016/j.xcrm.2025.102001","DOIUrl":"10.1016/j.xcrm.2025.102001","url":null,"abstract":"<p><p>Lighting interventions can mitigate fatigue by promoting circadian rhythmicity. We test whether individualized, wearable-based lighting interventions delivered via a mobile app reduce cancer-related fatigue in a randomized controlled trial with 138 breast cancer, prostate cancer, and hematopoietic stem cell transplant patients. Participants are randomized to tailored lighting intervention or control. The primary endpoint is PROMIS fatigue 4a at trial end, with secondary endpoints including change in daily fatigue, sleep, anxiety, depression, physical function, and overall health. Fatigue T-scores at week 11 do not differ between groups but decrease significantly from week 1 to week 11 (3.07 points, p = 0.001) in the intervention group, with a significant final-week treatment effect (p = 0.014). Daily fatigue, anxiety, sleep disturbance, and physical function improve within intervention. Further studies are needed to see if these results generalize in broader cancer care. The trial is registered at ClinicalTrials.gov (trial registration number: NCT04827446).</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102001"},"PeriodicalIF":11.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
